- Home
- HSPO vs MRNS Comparison
HSPO vs MRNS Comparison
Compare HSPO & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- MRNS
- Stock Information
- Founded
- HSPO 2014
- MRNS 2003
- Country
- HSPO United States
- MRNS United States
- Employees
- HSPO N/A
- MRNS N/A
- Industry
- HSPO Blank Checks
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- MRNS Health Care
- Exchange
- HSPO Nasdaq
- MRNS Nasdaq
- Market Cap
- HSPO 87.7M
- MRNS 104.7M
- IPO Year
- HSPO 2022
- MRNS 2014
- Fundamental
- Price
- HSPO $11.25
- MRNS $0.31
- Analyst Decision
- HSPO
- MRNS Buy
- Analyst Count
- HSPO 0
- MRNS 12
- Target Price
- HSPO N/A
- MRNS $4.56
- AVG Volume (30 Days)
- HSPO 27.4K
- MRNS 5.7M
- Earning Date
- HSPO 01-01-0001
- MRNS 11-05-2024
- Dividend Yield
- HSPO N/A
- MRNS N/A
- EPS Growth
- HSPO N/A
- MRNS N/A
- EPS
- HSPO 0.33
- MRNS N/A
- Revenue
- HSPO N/A
- MRNS $30,263,000.00
- Revenue This Year
- HSPO N/A
- MRNS $21.18
- Revenue Next Year
- HSPO N/A
- MRNS $56.42
- P/E Ratio
- HSPO $34.26
- MRNS N/A
- Revenue Growth
- HSPO N/A
- MRNS 16.56
- 52 Week Low
- HSPO $10.60
- MRNS $0.26
- 52 Week High
- HSPO $11.25
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- MRNS 21.75
- Support Level
- HSPO $11.17
- MRNS $0.29
- Resistance Level
- HSPO $11.25
- MRNS $1.96
- Average True Range (ATR)
- HSPO 0.00
- MRNS 0.12
- MACD
- HSPO 0.00
- MRNS -0.18
- Stochastic Oscillator
- HSPO 100.00
- MRNS 2.41
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.